FOXO Technologies signs agreement to acquire Vector Biosource Inc.

FOXO TECHNOLOGIES INC.

Purchase price: $500K cash, 60K Series E Preferred ($1.5M stated value), warrants for $2M common stock at 10% premium to closing price.
Up to additional 80K Series E Preferred shares ($2M stated value) contingent on future revenue and cash collection milestones.
FOXO to fund up to $1.2M for Vector's growth initiatives; Vector had Q2 2025 net revenue of ~$225K ($0.9M annualized).
Closing subject to due diligence, finalization of warrant and employment agreements; expected as soon as practical.
Vector provides data and biospecimen sourcing for biotech, clinical research, and pharma industries.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.